In 2014, there were a total of 1,299 mergers and acquisitions in the health care sector – a record number, up from 1,035 the year before. That includes a recent spike in pharmaceutical transactions, including inversions, which base U.S. drug companies overseas.
Speakers provided the latest information about the roles of the Department of Justice and the Federal Trade Commission; efforts by policymakers; the scope and extent of consolidation among doctors, hospitals, insurers and pharmaceutical companies; and implications for consumers and other stakeholders.
Deborah Feinstein, director of the Federal Trade Commission’s Bureau of Competition
Andrea Murino, partner and co-chair of Goodwin Procter’s antitrust practice
George Slover, senior policy counsel at Consumers Union
Alan Weil of Health Affairs and Marilyn Serafini of the Alliance for Health Reform moderated.
Full Transcript (Adobe Acrobat PDF)